Canaccord raised the firm’s price target on Arcellx to $66 from $49 and keeps a Buy rating on the shares. The firm noted Kite has excercised its option to negotiate a license for ACLX-001, the company’s second asset in multiple myeloma, using Arcellx’s ARC-Sparx technology. Kite will make a $200M equity investment for 3.2M shares at $61.68 per share as well as an $85M upfront cash payment.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ACLX: